U.S. Markets open in 5 hrs 41 mins

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
191.20-2.95 (-1.52%)
At close: 4:00PM EDT
People also watch
ALXNREGNBIIBVRTXCELG
  • A
    Alexis
    Alexis
    Is ILMN undervalued? This sort of setup suggests potential upside... awesom*sto-cks recently alerted this company i think. google them.
  • S
    Shirley
    Shirley

    I also received an alert for $ILMN from http://jcharlesassets.com/opiant-pharmaceuticals/?s=ILMN , any ideas? Investing making money. "hhse"

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • G
    Gerald
    Gerald
    Earnings easily topped expectations.
  • A
    Alajuela
    Alajuela
    Any guesses of where it'll move from here?
  • a
    angmed1
    angmed1
    AAPL and ILMN, romantic ideal couple.
  • C
    Crecy
    Crecy
    Nice move up. OT Must see AVEO...close to moving up higher...come to the Yahoo message board. Rx for Renal cancer-Tivozanib- Recommended for Approval. Date for Approval end Aug...SOON.
  • G
    Guru
    Guru
    down after hours?
  • j
    joe
    joe
    Test kit is huge deal should bring significant move.
  • P
    Pharmaherooooooo
    Pharmaherooooooo
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Y
    Yahoo Finance Insights
    Yahoo Finance Insights
    ILMN is down -4.92% to 168.94
  • B
    Bay Area
    Bay Area
    Wait, didn't this scam missed earnings and downwardly revised the guidance big time. Oh I forgot we are in the bubble so all that doesn't matter. But wait what will happen to #$%$ stocks like these when bubble finally goes bonker? It may happen starting Monday. Nasdaq wouldn't stop until it has falled 20-30% or more. Some are saying 80% drop, worst ever after 1929 and 2000.
  • C
    CURT2
    CURT2
    With a positive 700 million in equity after taking cash minus debt into account, and over 25 BILLION in stock value, this company could easily take out EXAS which poses an existential threat to the GRAIL initiative. The time to act is now however, soon their 3 Billion market cap will look like peanuts (See news re: UNH endorsement of the Cologuard Test and the non invasive test they've got on the front burner set to replace Lung Biopsy as a diagnostic tool. This could be highly accretive for ILMN and furthermore, I would HATE to see AMGN beat them to the punch and score here.
  • G
    Gordon
    Gordon
    Bought $181, not long ago; today added $176
  • J
    JERRY
    JERRY
    does Illumina buy Exact Science's (exas) or does Thermo Fisher (tmo) buy Exas first?
  • j
    joe
    joe
    Earnings always scary with this company , feeling better.
  • R
    RainbowMeow
    RainbowMeow
    Hey shorts - you were too clever by half in trying to peddle your fake news contamination story in front of earnings.
    How ya doing?
  • c
    chengis khan
    chengis khan

    https://www.wired.com/2017/04/geneticists-fear-illuminas-sequencers-may-distort-results/
    The Go-To Gene Sequencing Machine With Very Strange Results
    The Go-To Gene Sequencing Machine With Very Strange Results
    An update to Illumina's gene sequencing technology could have contaminated the results of recent high-sensitivity data produced on the machines.
    www.wired.com
    ReplyReplies (2)40

    The Go-To Gene Sequencing Machine With Very Strange Results
    An update to Illumina's gene sequencing technology could have contaminated the results of recent high-sensitivity data produced on the machines.
    www.wired.com
  • F
    Fast Eddie
    Fast Eddie
    I got out this morning in the green. Good luck longs.
  • m
    monkey
    monkey
    to make drugs and equipment, validation is key. lax validation processes lead to the facade of quality products...
    The Go-To Gene Sequencing Machine With Very Strange Results
    An update to Illumina's gene sequencing technology could have contaminated the results of recent high-sensitivity data produced on the machines.
    www.wired.com
  • t
    tmclev
    tmclev

    http://biorxiv.org/content/early/2017/04/09/125724
    This could be a huge issue for Illumina. It seems to be a problem with all of their new systems that rely upon exAMP.

    Index Switching Causes “Spreading-Of-Signal” Among Multiplexed Samples In Illumina HiSeq 4000 DNA Sequencing | bioRxiv
    bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
    biorxiv.org